Living Donor Liver Transplantation When Deceased Donor Is Not Possible or Timely: Case Examples and Ethical Perspectives

Josh Levitsky, Elisa J. Gordon – 24 December 2019 – This article analyzes the ethical soundness of living donor liver transplantation (LDLT) in situations where the transplant team does not consider deceased donor liver transplantation (DDLT) a clinical or timely option. Given that patients with end‐stage liver disease have a high risk of death without DDLT, the option of LDLT becomes compelling and may save lives.

Clinical Outcomes of Portosystemic Shunts on the Outcome of Liver Transplantation

Eduardo A. Rodriguez, Rachel Perez, Nan Zhang, Elisabeth S. Lim, Christopher Miller, Michael A. Schwartz, Aidan J. McGirr, Ananth Srinivasan, Winston Hewitt, Alvin C. Silva, Jorge Rakela, Hugo E. Vargas – 24 December 2019 – Spontaneous portosystemic shunts (SPSSs) have been associated with worse clinical outcomes in the pre–liver transplantation (LT) setting, but little is known about their post‐LT impacts. Our aim was to compare LT candidates with and without SPSSs and assess the impact of SPSSs on patient mortality and graft survival in the post‐LT setting.

TGF‐β Signaling Plays a Pivotal Role During Developmental Biliary Atresia in Sea Lamprey (Petromyzon marinus)

Yu‐Wen Chung‐Davidson, Jianfeng Ren, Chu‐Yin Yeh, Ugo Bussy, Belinda Huerta, Peter Joseph Davidson, Steven Whyard, Weiming Li – 24 December 2019 – Biliary atresia (BA) is a rare neonatal disease with unknown causes. Approximately 10% of BA cases develop in utero with other congenital defects that span a large spectrum of disease variations, including degeneration of the gall bladder and bile duct as well as malformation of the liver, intestines, and kidneys.

Icosabutate Exerts Beneficial Effects Upon Insulin Sensitivity, Hepatic Inflammation, Lipotoxicity, and Fibrosis in Mice

Anita M. Hoek, Elsbet J. Pieterman, José W. Hoorn, Marta Iruarrizaga‐Lejarreta, Cristina Alonso, Lars Verschuren, Tore Skjæret, Hans M.G. Princen, David A. Fraser – 24 December 2019 – Icosabutate is a structurally engineered eicosapentaenoic acid derivative under development for nonalcoholic steatohepatitis (NASH).

Vasoactive Intestinal Peptide Derived From Liver Mesenchymal Cells Mediates Tight Junction Assembly in Mouse Intrahepatic Bile Ducts

Ayako Sato, Sei Kakinuma, Masato Miyoshi, Akihide Kamiya, Tomoyuki Tsunoda, Shun Kaneko, Jun Tsuchiya, Taro Shimizu, Eiko Takeichi, Sayuri Nitta, Fukiko Kawai‐Kitahata, Miyako Murakawa, Yasuhiro Itsui, Mina Nakagawa, Seishin Azuma, Naohiko Koshikawa, Motoharu Seiki, Hiromitsu Nakauchi, Yasuhiro Asahina, Mamoru Watanabe – 24 December 2019 – Formation of intrahepatic bile ducts (IHBDs) proceeds in accordance with their microenvironment.

Model for End‐Stage Liver Disease With Additional Criteria to Predict Short‐Term Mortality in Severe Flares of Chronic Hepatitis B

James Fung, Lung‐Yi Mak, Albert Chi‐Yan Chan, Kenneth Siu‐Ho Chok, Tiffany Cho‐Lam Wong, Tan‐To Cheung, Wing‐Chiu Dai, Sui‐Ling Sin, Wong‐Hoi She, Ka‐Wing Ma, Wai‐Kay Seto, Ching‐Lung Lai, Chung‐Mau Lo, Man‐Fung Yuen – 23 December 2019

Subscribe to